Compounds > ncx 4040
Page last updated: 2024-11-11

ncx 4040

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID9818919
CHEMBL ID228226
SCHEMBL ID4138781
MeSH IDM0482305

Synonyms (23)

Synonym
[4-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate
no-aspirin
ncx4040
ncx 4040
CHEMBL228226
4-(nitrooxymethyl)phenyl 2-acetoxybenzoate
287118-97-2
2-(acetyloxy)benzoic acid 4-[(nitrooxy)methyl]phenyl ester
FT-0673021
SCHEMBL4138781
AKOS024458205
DTXSID60431311
2-[acetyloxy]benzoic acid 4-[nitrooxymethyl]phenylester
ncx 4040, >=98% (hplc)
2-acetoxy benzoic acid-4-nitrooxymethyl phenyl ester
J-017213
2-(acetyloxy)-4-[(nitrooxy)methyl]phenyl ester, benzoic acid
benzoic acid, 2-(acetyloxy)-, 4-[(nitrooxy)methyl]phenyl ester
MS-24981
2-(acetyloxy)-4-[(nitrooxy)methyl]phenyl ester,benzoic acid
CS-0027789
HY-103385
AKOS040745263
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID633573Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by trypan blue assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.
AID604378Cell cycle arrest in human HCT116 cells assessed as increase of phosphorylated histone H3 at Ser10 level at 20 to 40 uM after 24 hrs by Western blotting2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID1562201Drug metabolism in pH 7.5 PBS assessed as nitric oxide release at 50 uM measured after 90 mins in presence of nitrite by 2,3-diaminonaphthalene-based fluorescence assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
AID286680Induction of DNA fragmentation in human HT29 cells after 48 hrs by Nicoletti assay2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin.
AID604360Antiproliferative activity against human SK-BR-3 cells after 72 hrs by cell counting kit analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID604366Cell cycle arrest in human HCT116 cells assessed as accumulation at S phase at 40 uM after 24 hrs by FACS analysis (Rvb = 8.5 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID631765Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by trypan blue assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.
AID604361Antiproliferative activity against human MCF7 cells after 72 hrs by cell counting kit analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID631767Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by trypan blue assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.
AID1562202Drug metabolism in pH 7.5 PBS assessed as nitric oxide release at 50 uM measured after 90 mins in presence of K3[Fe(CN)6] by 2,3-diaminonaphthalene-based fluorescence assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
AID286678Induction of PARP cleavage in human HT29 cells after 8 hrs2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin.
AID604363Cell cycle arrest in human HCT116 cells assessed as accumulation at sub-G1 phase at 40 uM after 24 hrs by FACS analysis (Rvb = 6.2 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID604380Cell cycle arrest in human HCT116 cells assessed as increase of phosphorylated histone H3 at Ser10 level at 40 uM after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 1.4 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID286677Apoptosis induction in human HT29 cells after 24 hrs2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin.
AID604376Induction of apoptosis in human HCT116 cells at 40 uM after 24 hrs using FITC-TUNEL staining by flow cytometry2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID604364Cell cycle arrest in human HCT116 cells assessed as accumulation at G0/G1 phase at 40 uM after 24 hrs by FACS analysis (Rvb = 76.5 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID1562205Drug metabolism in human plasma assessed as S-nitroso-thiol level at 50 uM measured after 90 mins by 2,3-diaminonaphthalene-based fluorescence assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
AID1562203Drug metabolism in human plasma assessed as free nitrite level at 50 uM measured after 90 mins by 2,3-diaminonaphthalene-based fluorescence assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
AID604362Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by cell counting kit analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID286679Inhibition of serum-induced expression of cyclin D in human SW480 cells after 5 hrs2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin.
AID1562208Drug metabolism in pH 7.5 PBS assessed as S-nitroso-thiol level at 50 uM measured after 90 mins in presence of L-cysteine by 2,3-diaminonaphthalene-based fluorescence assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
AID604358Antiproliferative activity against human SW620 cells after 72 hrs by cell counting kit analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID631768Cytotoxicity against human SCC25 cells assessed as growth inhibition after 48 hrs by trypan blue assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.
AID604359Antiproliferative activity against human SW480 cells after 72 hrs by cell counting kit analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID286681Effect on cell death in HT29 cells pretreated with GSH synthesis inhibitor BSO2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin.
AID1562206Drug metabolism in pH 7.5 PBS assessed as free nitrite level at 50 uM measured after 90 mins in presence of L-cysteine by 2,3-diaminonaphthalene-based fluorescence assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
AID604383Induction of apoptosis in human HCT116 cells at 40 uM after 48 hrs using FITC-TUNEL staining by flow cytometry (Rvb = 7.3 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID631766Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by trypan blue assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.
AID604357Antiproliferative activity against human HCT116 cells after 72 hrs by cell counting kit analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID1238740Inhibition of Wnt/beta-catenin (unknown origin)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors.
AID1562204Drug metabolism in human plasma assessed as nitric oxide release at 50 uM measured after 90 mins by 2,3-diaminonaphthalene-based fluorescence assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
AID633574Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 48 hrs by trypan blue assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.
AID1562207Drug metabolism in pH 7.5 PBS assessed as nitric oxide release at 50 uM measured after 90 mins in presence of L-cysteine by 2,3-diaminonaphthalene-based fluorescence assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
AID633575Cytotoxicity against human LNCAP cells assessed as growth inhibition after 48 hrs by trypan blue assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.
AID604365Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 40 uM after 24 hrs by FACS analysis (Rvb = 10.9 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (50.00)29.6817
2010's10 (41.67)24.3611
2020's2 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.0610amino-acid anion
nitrates
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.		2.4620monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
acetovanillone
apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.		2.0210acetophenones;
aromatic ketone;
methyl ketone		antirheumatic drug;
EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug;
plant metabolite
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		5.51200benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
diphenyleneiodonium
diphenyleneiodonium: structure in first source; NADPH oxidase inhibitor. dibenziodolium : An organic cation that is fluorene in which the methylene group is replaced by a positively charged iodine.		2.0210organic cation
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.1510conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0310nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
molsidomine
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.. molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.		2.0210ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
quinone
benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).		2.03101,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite
linsidomine
linsidomine: RN given refers to parent cpd; structure		2.0210morpholines
vincristine
[no description available]		2.0610acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
benzanilide
[no description available]		2.0610
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.0610benzenes;
phenyl acetates
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0610taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
piloty's acid
Piloty's acid: structure in first source		2.2110sulfonamide
nitroaspirin
nitroaspirin: a nitric oxide donor		3.4370carbonyl compound
peroxynitrous acid
Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).		2.4110nitrogen oxoacid
erlotinib hydrochloride
[no description available]		2.2110hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
etodolac, (-)-isomer
(R)-etodolac : The R-enantiomer of etodolac. It is inactive, in contrast to the enantiomer, (S)-etodolac, which is a preferential inhibitor of cyclo-oxygenase 2 and a non-steroidal anti-inflammatory. The racemate is commonly used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain.		2.1110etodolac
tamoxifen citrate
[no description available]		2.2110citrate saltangiogenesis inhibitor;
anticoronaviral agent
tamoxifen
[no description available]		2.2110stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.8130prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
s-nitroso-n-acetylpenicillamine
S-Nitroso-N-Acetylpenicillamine: A sulfur-containing alkyl thionitrite that is one of the NITRIC OXIDE DONORS.		2.4420nitroso compound;
nitrosothio compound		nitric oxide donor;
vasodilator agent
salicylates
Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.		2.4320monohydroxybenzoateplant metabolite
cyclic gmp
Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.		2.02103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
2,2'-(hydroxynitrosohydrazono)bis-ethanamine
2,2'-(hydroxynitrosohydrazono)bis-ethanamine: a nitric oxide (NO) generating compound. 1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane : A nitroso compound that is triazane in which the the nitrogen at position 1 is substituted by two 2-aminoethyl groups, that at position 2 is substituted by a hydroxy group, and that at position 3 is substituted by an oxo group.		2.1110
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		02.7330
Colonic Neoplasms
Tumors or cancer of the COLON.		02.7330
Benign Neoplasms
[description not available]		03.6630
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.6630
Breast Cancer
[description not available]		02.2110
Malignant Melanoma
[description not available]		02.2110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.2110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.2110
Epithelial Ovarian Cancer
[description not available]		02.4110
Cancer of Ovary
[description not available]		02.5220
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.4110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.5220
Colorectal Cancer
[description not available]		02.610
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.610
Cancer of Prostate
[description not available]		02.2110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.2110
Stomatitis, Denture
Inflammation of the mouth due to denture irritation.		02.1510
Cancer of Lung
[description not available]		02.2110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.2110
Kahler Disease
[description not available]		02.1110
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		02.1110
Acute Respiratory Distress Syndrome
[description not available]		02.0210
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		02.0210
Bladder Cancer
[description not available]		02.0210
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.0210
Adenocarcinoma, Basal Cell
[description not available]		02.0310
Cancer of Pancreas
[description not available]		02.0310
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.0310
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.0310
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0410